Related Experiment Videos
Management issues in paroxysmal nocturnal hemoglobinuria
Gabrielle Meyers1, Charles J Parker
1Division of Hematology, University of Utah School of Medicine and VA Medical Center, Salt Lake City, Utah 84148, USA.
International Journal of Hematology
|March 12, 2003
Summary
Paroxysmal nocturnal hemoglobinuria (PNH) management involves distinguishing symptoms from bone marrow failure versus PIG-A mutant cell expansion. Complement inhibitors offer new hope for treating PNH hemolysis, while thrombophilia remains complex.
Area of Science:
- Hematology
- Genetics
- Immunology
Background:
- Paroxysmal nocturnal hemoglobinuria (PNH) originates from bone marrow injury.
- PNH is characterized by intravascular hemolysis and thrombophilia.
- Management decisions require differentiating symptoms of marrow failure from PIG-A mutant cell clone expansion.
Purpose of the Study:
- To review current understanding and management of Paroxysmal nocturnal hemoglobinuria (PNH).
- To discuss treatment options for hemolysis and thrombophilia in PNH.
- To address special considerations for pregnancy and bone marrow transplantation in PNH patients.
Main Methods:
- Literature review of PNH pathophysiology, clinical manifestations, and treatment strategies.
- Discussion of current therapeutic options, including complement inhibitors and anticoagulation.
- Exploration of future directions in PNH management, such as gene therapy and stem cell transplantation.
Main Results:
- Current treatments for PNH hemolysis are suboptimal, but complement inhibitors show promise.
- The basis of PNH thrombophilia is not fully understood, with anticoagulation as standard care.
- Bone marrow transplantation offers a cure but requires careful patient selection.
Conclusions:
- Effective management of PNH hemolysis is anticipated with complement inhibitors.
- Further research is needed to elucidate and treat PNH thrombophilia.
- Gene therapy and improved autotransplantation techniques are future goals for PNH treatment.